Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain.
about
Quantification of HER family receptors in breast cancerA phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancerFront-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study.Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study.Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimensHER2 expression in fine needle aspirates of lymph nodes detected by preoperative axillary ultrasound in breast cancer patients.Chemotherapy-induced polyneuropathy. Part I. Pathophysiology.Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancerHER-2/neu diagnostics in breast cancer.Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers.Gemcitabine and taxanes in metastatic breast cancer: a systematic review.Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.Serum HER2 as a response indicator to various chemotherapeutic agents in tissue HER2 positive metastatic breast cancer.Role of trastuzumab in the management of HER2-positive metastatic breast cancer.Gemcitabine in combination with paclitaxel for the treatment of metastatic breast cancer.Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure.Specific antibodies and sensitive immunoassays for the human epidermal growth factor receptors (HER2, HER3, and HER4).A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer.
P2860
Q27015506-1CC76641-9096-4F2A-8D06-F8044F6E3D9FQ33244593-FB19E773-356E-4F0F-8370-FE742E973977Q33363792-49E218EA-8E09-4F0E-8E23-380353FD7372Q33415078-18E6AB3F-92AA-4EFE-A6A8-F82D782DA880Q33735413-5B4EF77E-E163-42FC-A5DA-0E06EF924B3EQ34506643-4A010821-6481-4D30-9282-6FB98575E3E8Q34653461-55E665F5-7CBA-4739-B574-E1601343198EQ35854297-A307B67A-0E05-43C9-A95C-FC8F219AB1E4Q35906255-7A70E5FC-52FC-4122-95E4-701F585801CEQ36816042-B598B8DF-A0AB-4816-ABA5-0E75E1BB11FAQ37098132-A338CA97-719A-4F65-96B7-8FF01D8D002BQ37132369-9B537262-661E-4951-9B76-806A7B4DBC3EQ37341686-0872906D-A722-4CD9-BE34-159FBC5F8C1EQ37355370-768D2CA0-5517-48BB-8162-4F0F8B954ADFQ43267072-830B11CE-DFE0-4528-B0B8-EB17D9969E4FQ46727663-CBB3A542-F7E6-43DA-8E10-68A9FE8A6C1EQ50921156-93ED320E-3DE1-41F9-86EF-97248C61410FQ53402025-592479B6-13E6-43BE-9E4F-4FA5FA78B9FE
P2860
Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Biweekly paclitaxel plus gemci ...... of HER2 extracellular domain.
@en
Biweekly paclitaxel plus gemci ...... of HER2 extracellular domain.
@nl
type
label
Biweekly paclitaxel plus gemci ...... of HER2 extracellular domain.
@en
Biweekly paclitaxel plus gemci ...... of HER2 extracellular domain.
@nl
prefLabel
Biweekly paclitaxel plus gemci ...... of HER2 extracellular domain.
@en
Biweekly paclitaxel plus gemci ...... of HER2 extracellular domain.
@nl
P2093
P356
P1433
P1476
Biweekly paclitaxel plus gemci ...... e of HER2 extracellular domain
@en
P2093
A Barnadas
A Llombart-Cussac
J García-Conde
V Carañana
Y Fernández
P304
P356
10.1093/ANNONC/MDH048
P577
2004-02-01T00:00:00Z